{"id":2600,"date":"2023-02-19T22:07:12","date_gmt":"2023-02-19T20:07:12","guid":{"rendered":"https:\/\/www.vet-ebooks.com\/vetdrugslist\/?p=2600"},"modified":"2024-02-19T22:09:49","modified_gmt":"2024-02-19T20:09:49","slug":"robenacoxib","status":"publish","type":"post","link":"https:\/\/www.vet-ebooks.com\/vetdrugslist\/robenacoxib\/","title":{"rendered":"Robenacoxib"},"content":{"rendered":"

Robenacoxib In Dogs & Cats: Uses, Dosage and Side Effects<\/strong><\/p>\n

$\"Robenacoxib$ <\/p>\n\n

Overview<\/strong><\/h2>\n
\n
Mechanism of Action:<\/strong> Robenacoxib selectively inhibits the COX-2 enzyme, which reduces the production of prostaglandins involved in inflammation.<\/li>\n
Tissue Selectivity:<\/strong> Robenacoxib is considered tissue-selective, meaning it has a preference for distribution and concentration at sites of inflammation within the body.<\/li>\n
Short Half-Life:<\/strong> It has a short half-life in plasma, approximately 2 hours, which suggests that it is rapidly metabolized and eliminated from the bloodstream.<\/li>\n
Advantages:<\/strong> The combination of tissue selectivity and a short half-life may offer potential advantages, as it may reduce the exposure of target organs like the liver and kidneys to robenacoxib over a 24-hour dosing interval.<\/li>\n
Clinical Data:<\/strong> However, it’s important to note that there may not be sufficient clinical data to fully support these potential advantages at this time. Further research and clinical studies may be needed to confirm these benefits.<\/li>\n<\/ul>\n
Uses of Robenacoxib<\/strong><\/h2>\n
\n
Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.<\/li>\n
Reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery in dogs.<\/li>\n
Treatment of acute and chronic musculoskeletal pain and inflammation in cats.<\/li>\n<\/ul>\n
\n $\"Vet$ <\/a><\/div>\n\n
Dose of Robenacoxib in Dogs and Cats<\/strong><\/h2>\n
Dogs, Cats:<\/strong><\/p>\n
\n
2 mg\/kg s.c. q24h for a maximum of 2 doses; 1\u20132 mg\/ kg p.o. q24h.<\/li>\n
Monitoring of long-term treatment (>12 weeks) is recommended in cats and dogs.<\/li>\n<\/ul>\n
\n \n \n